Freenome received FDA Breakthrough Device Designation for its blood-based SimpleScreen lung cancer screening assay. The multiomic test combines a machine-learning classifier using DNA methylation and proteomics to identify adults ages 50 to 80 with at least a 20 pack-year smoking history who are not currently in guideline-recommended lung screening, with follow-up expected to rely on low-dose CT. In skin cancer, Natera and Kupando Therapeutics partnered for a Phase I trial in Germany using Natera’s Latitude circulating tumor DNA assay to monitor ctDNA dynamics during treatment with Kupando’s KUP-101. The collaboration aims to link serial MRD/ctDNA changes to immunotherapy response in advanced tumors across multiple skin cancer subtypes. These moves expand a broader push toward blood-based risk stratification and longitudinal molecular response tracking in oncology.